간행물

대한간암학회> 대한간암학회지

대한간암학회지 update

Journal of liver cancer

  • : 대한간암학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • :
  • : 연속간행물
  • : 반년간
  • : 2288-8128
  • : 2283-5001
  • : 대한간암연구회지(~2010)→대한간암연구학회지(2011~)

수록정보
수록범위 : 1권0호(2001)~19권2호(2019) |수록논문 수 : 480
대한간암학회지
19권2호(2019년 09월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Liver Transplantation in Mixed Hepatocellular Carcinoma and Cholangiocarcinoma

저자 : Jong Man Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 85-90 (6 pages)

다운로드

(기관인증 필요)

초록보기

Mixed hepatocellular carcinoma and cholangiocarcinoma (HCC-CC) are rare tumors, and the risk factors associated with them are not well understood yet. Moreover, the diagnosis of mixed HCC-CC can be complicated due to the difficulty in distinguishing mixed HCC-CC from HCC and intrahepatic CCC on radiological images. Serum tumor markers are useful when the radiological images are inconclusive. It remains unclear whether the prognosis of mixed HCC-CC differs from that of HCC. However, several studies have reported that the tumor recurrence and patient survival rates of mixed HCC-CC were similar to those of HCC after liver transplantation (LT) and liver resection. In this paper, we report that LT in patients with mixed HCC-CC achieves outcomes which are similar to those seen in LT for HCC. Therefore, the diagnosis of mixed HCC-CC should not be considered as a contraindication for LT. (J Liver Cancer 2019;19:85-90)

KCI등재

2Contrast-enhanced Ultrasonography: The Third Modality for Differentia-tion of Liver Mass

저자 : Min Kyu Kang , Moon Young Kim , Seong Hee Kang , Soon Koo Baik

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 91-96 (6 pages)

다운로드

(기관인증 필요)

초록보기

Contrast-enhanced ultrasonography (CEUS) using microbubble ultrasonography contrast agent can show the vascular structure and unique contrast enhancement patterns of focal liver lesions, including hepatocellular carcinoma (HCC). CEUS shows three phases, similar to a vascular pattern on computer tomography (CT), and typical arterial enhancement and portal or late phase washout in HCC. CEUS can show real-time images without nephrotoxicity or radiation hazard and can be used as guidance for loco-regional treatment and estimation of treatment response of HCC. In addition, some data recently revealed the usefulness of CEUS in the early estimation of response to anti-cancer pharmacological (i.e., sorafenib) therapy in advanced HCC. Although CEUS has limitations in clinical practice and more investigation is needed for its validation, it is recommended as a main diagnostic modality in a few major clinical practice guidelines for HCC. Thus, greater understanding of CEUS is necessary to extend its application in real practice for diagnosis and management of diseases. (J Liver Cancer 2019;19:91-96)

KCI등재

3The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma

저자 : Sun Young Yim , Ju-seog Lee

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 97-107 (11 pages)

다운로드

(기관인증 필요)

초록보기

The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification of the common underlying molecular alterations. The tumor microenvironment, regulated by inflammatory cells, including cancer cells, stromal tissues, and the surrounding extracellular matrix, has been extensively studied using molecular data. The integration of molecular, immunological, histopathological, and clinical findings has provided clues to uncover predictive biomarkers to enhance responses to novel therapies. Herein, we provide an overview of the current HCC genomic landscape, previously identified gene signatures that are used routinely to predict prognosis, and an immune-specific class of HCC. Since biomarker-driven treatment is still an unmet need in HCC management, translation of these discoveries into clinical practice will lead to personalized therapies and improve patient care, especially in the era of targeted and immunotherapies. (J Liver Cancer 2019;19:97-107)

KCI등재

4Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma

저자 : Hye Won Lee , Kyung Joo Cho , Soon Young Shin , Ha Yan Kim , Eun Ju Lee , Beom Kyung Kim , Seung Up Kim , Jun Yong Park , Do Young Kim , Sang Hoon Ahn , Kwang-hyub Han

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 108-116 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Programmed death receptor 1 (PD-1) is a promising new target for treatment of patients with hepatocellular carcinoma (HCC). A high expression level of programmed death-ligand 1 (PD-L1) is a possible prognostic indicator for poor outcome in other malignancies. Here, we investigated the clinical significance of PD-1 and PD-L1 in patients with HCC.
Methods: We enrolled patients with HCC who underwent surgical resection at Severance Hospital between 2012 and 2017 and investigated the levels of PD-L1 in HCC tissues (tPD-L1) and PD-L1/PD-1 in serum (sPD-L1/sPD-1). We also aimed to determine whether expression levels correlated with clinical and histological features.
Results: A total of 72 patient samples were analyzed. The median sPD-L1 and sPD-1 levels were 25.72 and 341.44 pg/mL, respectively. A positive correlation was detected between tPD-L1 and sPD-1 levels (R2=0.426, P< 0.001). The median sPD-1 level increased linearly with tPD-L1 score (P=0.002). During the follow-up period, HCC recurred in eight (11.1%) patients and liverrelated mortality occurred in eight (11.1%) patients. Higher sPD-L1 levels (≥19.18 pg/mL) tended to be associated with liver-related mortality (hazard ratio 6.866; 95% confidence interval, 0.804-58.659, P=0.078). sPD-1 levels of patients treated with nivolumab as a second-line therapy changed serially, and a >50% reduction in sPD-1 levels was observed immediately after nivolumab administration. However, sPD-1 level was not associated directly with prognosis in patients with advanced HCC.
Conclusions: The results demonstrated that PD-L1 and PD-1 levels changed according to the immunotherapy. However, no significant association with clinical outcome in patients with HCC was detected. (J Liver Cancer 2019;19:108-116)

KCI등재

5An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era

저자 : Chan Uk Lee , Young-sun Lee , Ji Hoon Kim , Minjin Lee , Sehwa Kim , Young Kul Jung , Yeon Seok Seo , Hyung Joon Yim , Jong Eun Yeon , Kwan Soo Byun

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 117-127 (11 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to investigate the prognosis predictors and the role of second-line cytotoxic systemic chemotherapy (CSC) in patients with advanced HCC after sorafenib discontinuation in the pre-regorafenib era.
Methods: From 2007 to 2015 in the pre-regorafenib era, the medical records of 166 HCC patients, who had permanently discontinued sorafenib, were retrospectively reviewed. For further analysis of survival factors after sorafenib treatment failure, we compared the survival of patients who had maintained liver function after second-line treatment with the best supportive care (BSC) group and selective BSC (SBSC) group.
Results: After discontinuation of sorafenib, median overall survival (OS) was 2.8 (1.9-3.7) months. The OS in patients who discontinued sorafenib due to adverse effect, progression, and poor clinical condition were 5.5 (2.4-8.6), 5.5 (2.2-8.9), and 0.9 (0.5-1.3) months, respectively (P<0.001). The independent predictive factors of survival after sorafenib failure were serum level of bilirubin and albumin, α-fetoprotein, discontinuation cause, and second-line CSC. In comparison with survival between second-line CSC and BSC group, the CSC group showed better survival outcome compared to the BSC group (10.6 vs. 1.6 months, P<0.001) and SBSC group (10.6 vs. 4.2 months, P=0.023).
Conclusions: The survival after sorafenib failure in patients who discontinued sorafenib due to progression and adverse effects was significantly better than in those who discontinued treatment due to clinical deterioration. In the pre-regorafenib era, patients who received second-line CSC showed better survival than those who received only supportive care after sorafenib failure. (J Liver Cancer 2019;19:117-127)

KCI등재

6Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

저자 : Young Youn Cho , Young Hwan Choi , Su Jong Yu , Eun Ju Cho , Jeong-hoon Lee , Yoon Jun Kim , Jung-hwan Yoon

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 128-135 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury. The aim of this study was to determine whether TDF is associated with more renal adverse events than entecavir (ETV) in HCC patients treated with TACE.
Methods: In this retrospective single-center study, we selected 53 HCC patients who were treated with TDF from January 2012 to July 2013 and had their first TACE procedure in the same period. These patients were matched by age and sex to patients treated with ETV.
Results: There were no significant differences in baseline characteristics, including HCC factors, and nephrotoxic drug use, between the two groups. The median follow-up period was 17.0 and 20.0 months for the TDF and ETV groups, respectively. There was no difference during the follow-up period between the TDF and ETV groups in the increase in creatinine over 0.5 mg/dL (17.0% and 17.0%, P=1.00, respectively) and the decrease in eGFR over 25% (43.4% and 41.5%, P=0.84, respectively). Multivariate analysis revealed that Child-Pugh class over B (hazard ratio [HR], 7.30; 95% confidence interval [CI] 2.79-19.10; P<0.01) was associated with increase in creatinine, and Child-Pugh class over B (HR, 82.74; 95% CI 12.31-555.83; P<0.01) and Barcelona-Clinic Liver Cancer stage over B (HR, 14.93; 95% CI 1.60-139.51; P=0.02) were associated with decrease in eGFR.
Conclusions: TDF has comparable safety to that of ETV for HCC patients undergoing TACE. (J Liver Cancer 2019;19:128-135)

KCI등재

7Radiation-induced Myositis after Proton Beam Therapy to Huge Hepatocellular Carcinoma

저자 : Jihye Kim , Gyu Sang Yoo , Dong Hyun Sinn , Hee Chul Park , Kwang Cheol Koh

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 136-142 (7 pages)

다운로드

(기관인증 필요)

초록보기

Proton beam therapy (PBT) is one of the advances in radiotherapy techniques, which enables dose escalation with lower probability of radiation-induced liver or gastrointestinal injuries. However, the chest wall proximal to the tumor can be affected by high dose irradiation. Here, we report on a 58-year-old male patient who presented with huge hepatocellular carcinoma, received treatment with transarterial chemoembolization and PBT, and developed severe chest wall pain due to radiation-induced myositis. The patient's symptoms were controlled by oral steroids. (J Liver Cancer 2019;19:136-142)

KCI등재

8Malignant Hepatic Solitary Fibrous Tumor

저자 : Hong Il Kim , Seok Kyung In , Hyung Suk Yi , Min Jeong Lee , Hyo Young Kim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 143-148 (6 pages)

다운로드

(기관인증 필요)

초록보기

Hepatic solitary fibrous tumors (SFTs) are mostly benign and rare because of information regarding the clinical symptoms, treatment, and prognosis of their malignant forms is currently lacking. A literature review concerning malignant SFTs revealed that there were a few cases where patients experienced abdominal right upper quadrant (RUQ) pain as their first clinical symptom, and metastases were found after being diagnosed with hepatic SFT. Here, we report a patient who was previously healthy without any clinical symptoms such as RUQ pain or weight loss, but had the appearance of a metastatic mass as the first clinical presentation before a primary hepatic SFT was detected (J Liver Cancer 2019;19:143-148)

KCI등재

9Long-term Disease-free Survival after Trimodality Treatment of Recurrent Hepatocellular Carcinoma Involving the Inferior Vena Cava and Right Atrium

저자 : Sunmin Park , Won Sup Yoon , Hyung Joon Yim , Chai Hong Rim

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 149-153 (5 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) involving the inferior vena cava (IVC) and/or right atrium (RA) is a rare and intractable disease. A standard treatment has not been established yet, owing to the rarity of disease and difficulties in the therapeutic treatment. Herein, we report the case of a patient who had recurrent HCC (after a prior lobectomy) involving both IVC and RA and underwent multimodality treatments including external beam radiotherapy and transarterial chemotherapy, followed by sorafenib treatment. The disease was well controlled with local treatments and sustained for 7 years until last follow-up after the systemic treatments. Our case shows a possibility of long-term survival for patients affected by HCC involving IVC and/ or RA, after a rigorous multimodality treatment strategy. (J Liver Cancer 2019;19:149-153)

KCI등재

10Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event

저자 : Dae-ha Kim , Minkoo Kim , Hyung Joon Yim , Sang Jun Suh , Young Kul Jung

발행기관 : 대한간암학회 간행물 : 대한간암학회지 19권 2호 발행 연도 : 2019 페이지 : pp. 154-158 (5 pages)

다운로드

(기관인증 필요)

초록보기

A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved. (J Liver Cancer 2019;19:154-158)

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

부산대학교 진주보건대학교 세명대학교 육군사관학교 전남대학교
 27
 21
 10
 9
 8
  • 1 부산대학교 (27건)
  • 2 진주보건대학교 (21건)
  • 3 세명대학교 (10건)
  • 4 육군사관학교 (9건)
  • 5 전남대학교 (8건)
  • 6 동의과학대학교 (8건)
  • 7 경운대학교 (7건)
  • 8 연세대학교 (7건)
  • 9 신성대학교 (6건)
  • 10 경남대학교 (5건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기